At a Glance
Roche Venture Fund serves as the strategic investment arm of pharmaceutical giant Roche, launched to identify and invest in promising early-stage healthcare innovations. The fund operates with a dual mandate: generating financial returns while creating strategic value for Roche through access to cutting-edge technologies and potential partnership opportunities. RVF focuses on companies developing novel therapeutics, advanced diagnostics, and digital health solutions that could complement or enhance Roche's existing portfolio in oncology, immunology, neuroscience, and infectious diseases. The fund leverages Roche's deep scientific expertise and global infrastructure to provide portfolio companies with more than just capital, offering regulatory guidance, clinical development support, and potential pathways to commercialization. This strategic approach allows RVF to participate in the broader healthcare innovation ecosystem while maintaining alignment with Roche's long-term strategic objectives.
“Investing in breakthrough healthcare innovations that can transform patient outcomes and advance personalized medicine.”
Foundation Medicine
Flatiron Health
Alnylam
Relay TherapeuticsRoche Venture Fund primarily invests at the Series A, Series B+ stages. This means they focus on companies that are scaling their go-to-market after proving product-market fit.
Roche Venture Fund is headquartered in Basel, Switzerland. Many of their portfolio companies are also based in this region, though they invest across geographies.
Roche Venture Fund focuses on investments in Biotech, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.
Roche Venture Fund's typical investment check size ranges from $5M to $30M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Roche Venture Fund manages approximately $1.5B in assets under management (AUM) across their funds.